The present study was designed to investigate the time course of alterations in β1- and β2-adrenoceptor subtypes, α2-adrenoceptors and uptake sites for norepinephrine in the rat brain following thyroidectomy (TXT) and thyroxine replacement. The results indicate that alterations in the thyroid state lead to changes in the pre- and postsynaptic noradrenergic system that are both region- and receptor-specific. TXT caused the binding of 125-iodopindolol to β1-adrenoceptors to decrease in the cortex and hippocampus and caused its binding to β2-adrenoceptors to decrease in the hypothalamus. TXT caused 3H-idazoxan binding to α2-adrenoceptors to be reduced specifically in the amygdala. Following TXT, the binding of 3H-nisoxetine to norepinephrine uptake sites was found to be increased in the hippocampus and decreased in the hypothalamus. In most brain regions, thyroxine replacement for 7 or 28 days caused radioligand binding to recover to control levels. Thus it appears that a neuromodulatory link between thyroid hormone and the noradrenergic system exists in many regions of the rat brain.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.